Aquestive Therapeutics, Inc. (AQST) stock forecast and price target
Price $3.91 · data as of November 13, 2026
12-month price target
Average target$9.33
Upside / downside+138.7%
Analysts9
ConsensusStrong buy
Low $6.00Average $9.33High $11.00
Gold marker: average target · white marker: today’s price ($3.91)
Analyst ratings
Strong buy 2Buy 7Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.40 | +32.1% | $50M |
| Next fiscal year ends December 31, 2027 | $-0.58 | −45.0% | $70M |
| Next quarter ends December 31, 2026 | $-0.11 | +22.4% | $14M |
| Quarter after ends March 31, 2027 | $-0.15 | −237.7% | $11M |
Consensus of the analysts covering Aquestive Therapeutics, updated daily. In the last 30 days 1 estimates were raised and 0 lowered.
Frequently asked questions
What is the Aquestive Therapeutics stock price target?
The average 12-month target from 9 analysts is $9.33, 138.7% above the current price of $3.91 Targets range from $6.00 to $11.00.
Is Aquestive Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (2 strong buy, 7 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Aquestive Therapeutics expected to earn?
Analysts expect EPS of $-0.40 for the fiscal year ending December 31, 2026 and $-0.58 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.